On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
January 07, 2019
Nuvectra® Announces Preliminary Unaudited Fourth Quarter and Full Year 2018 Revenue
PLANO, Texas, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Preliminary unaudited consolidated revenue in the fourth quarter of 2018 is expected to be in the range of $15.3 to $15.7 million, compared to $12.0 million in the fourth quarter of 2017. Preliminary unaudited Algovita revenue in the fourth quarter of 2018 is
January 02, 2019
Nuvectra Announces Divesture of NeuroNexus Subsidiary
PLANO, Texas, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it has entered into an agreement effective December 31, 2018, to sell its wholly owned subsidiary NeuroNexus Technologies, Inc. (“NeuroNexus”) to NEL Group, Inc., an entity affiliated with certain former employees of NeuroNexus, for $5.0 million in cash. NeuroNexus will operate as a separate entity following the sale. NeuroNexus designs, manufactu
The Ruth Group
|There are currently no events scheduled.|